Company news

Madrigal Pharmaceuticals, Inc. news in 2025

Madrigal Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 14, 2025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

November 16, 2025

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

November 9, 2025

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

November 3, 2025

Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025

October 27, 2025

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

October 21, 2025

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

September 2, 2025

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

August 18, 2025

Credo AI Launches Advisory Services to Make Trusted AI Governance Real, Auditable, and Measurable

August 12, 2025

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 10, 2025

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

August 4, 2025

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

July 29, 2025

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

July 24, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

July 21, 2025

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

July 15, 2025

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

June 19, 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

June 1, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 9, 2025

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

April 30, 2025

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

April 28, 2025

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

April 17, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

April 15, 2025

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

March 10, 2025

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

February 25, 2025

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

February 25, 2025

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

February 20, 2025

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

February 11, 2025

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

January 12, 2025

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 2, 2025

Calls in 2025

Decks in 2025